These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1806 related items for PubMed ID: 18852664

  • 21. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW, Schmidt-Hieber M, Leschinger N, Göldner H, Knauf W, Hopfenmüller W, Thiel E, Blau O.
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS, Kang YA, Seol M, Ryu SG.
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. T-cell receptor Vbeta repertoire after myeloablative and reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
    Hentschke P, Omazic B, Mattsson J, Näsman-Björk I, Lundkvist I, Gigliotti D, Barkholt L, Ringdén O, Remberger M.
    Scand J Immunol; 2005 Mar; 61(3):285-94. PubMed ID: 15787747
    [Abstract] [Full Text] [Related]

  • 30. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I.
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [Abstract] [Full Text] [Related]

  • 31. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y, Yoshihara S, Hoshida Y, Inoue T, Fujioka T, Ikegame K, Kawakami M, Masuda T, Aozasa K, Kawase I, Ogawa H.
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [Abstract] [Full Text] [Related]

  • 32. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
    Chan GW, Gorgun G, Miller KB, Foss FM.
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
    [Abstract] [Full Text] [Related]

  • 33. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J.
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
    [Abstract] [Full Text] [Related]

  • 34. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rupa-Matysek J, Lewandowski K, Nowak W, Sawiński K, Gil L, Komarnicki M.
    Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
    [Abstract] [Full Text] [Related]

  • 35. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A, Tang X, Chang H, Zhu Z.
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [Abstract] [Full Text] [Related]

  • 36. Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease.
    Lau J, Sartor M, Bradstock KF, Vuckovic S, Munster DJ, Hart DN.
    Transplantation; 2007 Apr 15; 83(7):839-46. PubMed ID: 17460553
    [Abstract] [Full Text] [Related]

  • 37. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors.
    Koh LP, Rizzieri DA, Chao NJ.
    Biol Blood Marrow Transplant; 2007 Nov 15; 13(11):1249-67. PubMed ID: 17950913
    [Abstract] [Full Text] [Related]

  • 38. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
    Yamasaki S, Heike Y, Mori S, Fukuda T, Maruyama D, Kato R, Usui E, Koido K, Kim S, Tanosaki R, Tobinai K, Teshima T, Takaue Y.
    Transpl Infect Dis; 2008 Jul 15; 10(4):252-9. PubMed ID: 18194371
    [Abstract] [Full Text] [Related]

  • 39. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE.
    Int Immunopharmacol; 2003 Aug 15; 3(8):1121-43. PubMed ID: 12860168
    [Abstract] [Full Text] [Related]

  • 40. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J, Vazquez A, Crocchiolo R, Furst S, Calmels B, Castagna L, Lemarie C, Granata A, Ladaique P, Oudin C, Faucher C, Chabannon C, Blaise D.
    Am J Hematol; 2012 Dec 15; 87(12):1074-8. PubMed ID: 22911907
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 91.